

Supplementary Online Content

Manuscript: “**Central nervous system complications associated with immune checkpoint inhibitors**”

Supplementary Table. Evolution of brain metastases at onset of immune checkpoint inhibitor-induced CNS toxicity

Supplementary References.

Supplementary Table: Evolution of brain metastases at onset of immune checkpoint inhibitor-induced CNS toxicity

| Patient N° | N° of brain metastases | Location of brain metastases, lobe(s) | Evolution of the metastases at the time of CNS-ICI onset | Appearance of inflammatory brain lesion distant from metastases (type) | Ab | CNS-ICI syndrome |
|------------|------------------------|---------------------------------------|--|--|------|---------------------|
| 3 | 2 | R precentral gyrus R frontal | Complete regression Almost complete regression | No | Ma2 | Limbic encephalitis |
| 4 | 1 | R frontal | Stable | Yes (bilateral limbic involvement) | Ma2 | Limbic encephalitis |
| 11 | 2 | L cerebellar R temporal | Almost complete regression of both | Yes (diffuse perivascular post-gadolinium enhancement) | GFAP | Meningoencephalitis |
| 12 | 2 | R frontal L occipital | Stable Size reduction | No | GFAP | Meningoencephalitis |
| 15 | 1 | Supratentorial (location N.A.) | Complete regression | No | - | Cerebellar syndrome |
| 18 | 1 | L occipital | Size reduction | No | - | Isolated confusion |

Abbreviations: Ab, antibody; CNS, central nervous system; GFAP, glial fibrillary acidic protein; ICI, immune checkpoint inhibitor; L, left; N.A., not available; R, right

Supplementary references:

1. Aya F, Ruiz-Esquide V, Viladot M, et al. Vasculitic neuropathy induced by pembrolizumab. *Ann Oncol*. 2017;28:433–434.
2. Baird-Gunning JJD, Weerasinghe D, Silsby M, et al. Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma. *Neurohospitalist*. 2018;8:191–193.
3. Barp A, Gilardin L, Afanasiev V, et al. Subacute inflammatory demyelinating polyradiculoneuropathy complicating relapsing Hodgkin lymphoma: another immune-related adverse event of the anti-PD1 therapy? *Leuk Lymphoma*. 2019;60:547–549.
4. Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. *J Immunother*. 2009;32:203–205.
5. Cafuir L, Lawson D, Desai N, Kesner V, Voloschin A. Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. *J Immunother Cancer*. 2018;6:11.
6. Cho H-S, Lee K-Y, Hu C-J, Chung C-C. Severe polyradiculoneuritis associated with the combination of ipilimumab and pembrolizumab in a lung cancer patient. *Neurol India*. 2018;66:509–511.
7. de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. *N Engl J Med*. 2016;375:296–297.
8. Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. *J Neurol Neurosurg Psychiatry*. 2018;89:435–437.
9. Gambichler T, Susok L, Fels M, et al. Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female patient with melanoma. *Br J Dermatol*. Epub 2019 Jul 19.
10. Gaudy-Marqueste C, Monestier S, Franques J, Cantais E, Richard M-A, Grob J-J. A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. *J Immunother*. 2013;36:77–78.
11. Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. *J Clin Neurosci*. 2017;45:14–17.
12. Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. *J Cancer Res Clin Oncol*. 2016;142:1869–1870.
13. Jinnur P, Lim KG. Severe Acute Orthopnea: Ipilimumab-Induced Bilateral Phrenic Nerve Neuropathy. *Lung*. 2015;193:611–613.

14. Kelly Wu W, Broman KK, Brownie ER, Kauffmann RM. Ipilimumab-induced Guillain-Barré Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy. *J Immunother*. 2017;40:196–199.
15. Kyriazoglou A, Lontos M, Papadopoulos C, et al. Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. *Clin Genitourin Cancer*. 2019;17:e360–e364.
16. Lacour M, Grangeon L, Flament J, et al. Ipilimumab-induced severe meningoradiculitis. *J Clin Neurosci*. 2019;62:246–247.
17. Manam R, Martin JL, Gross JA, et al. Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy. *Cureus*. 2018;10:e3371.
18. Manousakis G, Koch J, Sommerville RB, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. *Muscle Nerve*. 2013;48:440–444.
19. Nukui T, Nakayama Y, Yamamoto M, et al. Nivolumab-induced acute demyelinating polyradiculoneuropathy mimicking Guillain-Barré syndrome. *J Neurol Sci*. 2018;390:115–116.
20. Ong S, Chapman J, Young G, Mansy T. Guillain-Barré-like syndrome during pembrolizumab treatment. *Muscle Nerve*. Epub 2018 Feb 14.
21. Alhammad RM, Dronca RS, Kottschade LA, et al. Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. *Mayo Clin Proc Innov Qual Outcomes*. 2017;1:192–197.
22. Porambo ME, Sedarsky KE, Elliott EJ, Theeler BJ, Smith JK. Nivolumab-induced neuralgic amyotrophy with hourglass-like constriction of the anterior interosseous nerve. *Muscle Nerve*. 2019;59:E40–E42.
23. Rupareliya C, Naqvi S, Jani VB. Acute Inflammatory Demyelinating Polyneuroradiculopathy with Ipilimumab in Metastatic Melanoma: A Case Report and Review of Literature. *Cureus*. 2017;9:e1310.
24. Schneiderbauer R, Schneiderbauer M, Wick W, Enk AH, Haenssle HA, Hassel JC. PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma. *Acta Derm Venereol*. 2017;97:395–396.
25. Sepúlveda M, Martinez-Hernandez E, Gaba L, et al. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. *Muscle Nerve*. 2017;56:E162–E167.
26. Supakornnumporn S, Katirji B. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review. *J Clin Neuromuscul Dis*. 2017;19:80–83.
27. Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. *Jpn J Clin Oncol*. 2016;46:875–878.

28. Thaipisuttikul I, Chapman P, Avila EK. Peripheral neuropathy associated with ipilimumab: a report of 2 cases. *J Immunother*. 2015;38:77–79.
29. Thapa B, Khalid S, Vakili R, Ui J, Misbah S. Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer. *Am J Ther*. 2018;25:e761–e763.
30. Villarreal-Compagny M, Iglesias P, Marco-Hernández J, et al. ANCA-associated vasculitic neuropathy during treatment with ipilimumab. *Rheumatology (Oxford)*. 2020;59:251–252.
31. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. *Ann Oncol*. 2011;22:991–993.
32. Yildirim N, Gonen M, Balgetir F, Er MB. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review. *Clin Genitourin Cancer*. 2019;17:e1104–e1107.
33. Green KE, Levine AM, Ward JH, Kaufman DI. GQ1b-Seronegative Miller Fisher Syndrome Associated With Pembrolizumab. *J Neuroophthalmol*. 2019;39:394–396.
34. Luke JJ, Lezcano C, Hodi FS, Murphy GF. Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. *J Clin Oncol*. 2015;33:e32-35.
35. Seery V. Interprofessional Collaboration with Immune Checkpoint Inhibitor Therapy: the Roles of Gastroenterology, Endocrinology and Neurology. *Semin Oncol Nurs*. 2017;33:402–414.
36. Yen C-C, Su H-C, Chu C-Y, et al. Excellent treatment response with pembrolizumab in a lung cancer patient who developed immune-mediated acute motor/sensory axonal polyneuropathy. *Lung Cancer*. 2018;120:149–151.
37. Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. *Neurology*. 2019;93:e1093–e1103.